Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease area (Oncology, Autoimmune & Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) - Global Forecast to 2028

Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease area (Oncology, Autoimmune & Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) - Global Forecast to 2028

The antibody therapeutics market is expected to reach USD 479.0 billion by 2028 from USD 247.3 billion in 2023, at a CAGR of 14.1%during the forecast period. The key factors driving the growth of the antibody therapeutics market include the increasing number of product approvals in the last five years and growing advancements in antibody engineering, among others. Moreover, growth avenues in emerging economies are an opportunity area for this market.

The antibody therapeutics market has been segmented based on format, disease area, route of administration, source, end user and region.

“By source, the human source segment accounted for the largest share of the antibody therapeutics market.”

Based on source, the antibody therapeutics market is categorized into human, humanized, chimeric and other sources. In 2022, humanized sources accounted for the highest growth rate owing to factors such as The rising demand for therapies (including antibody therapy) against cancer,increasing cancer prevalence, high effectiveness of humanized sourced antibodies against cancers and autoimmune & inflammatory diseases are the major factors driving the growth of this segment.

“By route of administration, the intravenous segment accounted for the largest share in the antibody therapeutics market.”

Based on the route of administration, the antibody therapeutics market is segmented into the intravenous, subcutaneous and other routes of administration. In 2022, the intravenous route segment accounted for the largest share of the antibody therapeutics market. Growth in this market segment can be attributed to ease of administration, high effectiveness, presence of large marketed products and major focus of pipeline products on intravenous route.

“North America: the largest share of the antibody therapeutics market.”

North America accounted for the largest share of the antibody therapeutics market. The large share of the North American region can be attributed to major factors such presence of technologically advanced infrastructure in healthcare settings offering antibody therapeutics, and easy accessibility to advanced therapeutics among others. Besides, the region has a well established healthcare system which further supports the growth of this market. Also, the presence of some of the key players in the market is another key factor. Some examples of these players include AbbVie Inc. (US), Johnson & Johnson (US), and Bristol-Myers Squibb (US).

“Europe: The fastest-growing region in the antibody therapeutics market.”

The European antibody therapeutics market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors including the growing initiatives for advancements of antibody therapeutics, increasing prevalence of chronic diseases and key players such as F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Sanofi (France) operating in the region.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%

By Designation: Managers - 45%, Directors- 30%, and Executives - 25%

By Region: North America- 25%, Europe- 25%, Asia Pacific- 40%, Latin America- 5%, and Middle East- 3% & Africa- 2%

ProminentPlayers

F. Hoffmann-La Roche Ltd. (Switzerland)

AbbVie Inc. (US)

Johnson & Johnson (US)

Merck KGaA (Germany)

Bristol-Myers Squibb (US)

AstraZeneca (UK)

Sanofi (France)

Regeneron Pharmaceuticals, Inc. (US)

Novartis AG (Switzerland)

Amgen, Inc. (US)

Biogen Inc. (US)

Takeda Pharmaceutical Company Limited (Japan)

Pfizer Inc. (US)

Eli Lilly and Company (US)

Boehringer Ingelheim International GmbH (Germany)

GlaxoSmithKline plc (UK)

UCB, Inc. (Belgium)

Emergent BioSolutions Inc. (US)

Y-mAbs Therapeutics, Inc. (US)

Teva Pharmaceutical Industries Limited (Israel)

Ultragenyx Pharmaceutical Inc. (US)

Lundbeck A/S (Denmark)

Celltrion, Inc. (South Korea)

MacroGenics, Inc. (US)

MorphoSys AG (Germany)

Research Coverage:

This report provides a detailed picture of the antibody therapeutics market. It aims at estimating the size and future growth potential of the market across different segments, such as the format, disease area, route of administration, source, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the antibody therapeutics market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges. Additionally, the report is inclusive of extensive product mapping along with their revenues. The report also gives pipeline analysis of antibody therapeutic products which are expected to impact the market significantly during the forecast period.

The report provides insights on the following pointers”

Analysis of key drivers (growth in regulatory approvals for antibody therapeutics products), opportunities (emerging economies), restraint (stringent regulations) and challenges (manufacturing complexities) influencing the growth of the antibody therapeutics market.

Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the antibody therapeutics market.

Market Development:Comprehensive information about lucrative markets- the report analyses the antibody therapeutics market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the antibody therapeutics market.

Analysis of clinical pipeline data and data on products estimated to be launched during the forecast period.

Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (US), Johnson & Johnson (US), Merck KGaA (Germany), Bristol-Myers Squibb (US), AstraZeneca (UK), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Biogen Inc. (US) among others in the antibody therapeutics market.